Allogene Therapeutics, Inc. ALLO

ALLO Company Overview

Allogene Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic chimeric antigen receptor T cell (AlloCAR T) therapies for cancer. The company operates within the biotechnology and cell therapy industries, with a primary emphasis on hematologic malignancies and solid tumors. Unlike autologous CAR T therapies that use a patient’s own cells, Allogene’s platform is designed to manufacture “off-the-shelf” CAR T products from healthy donor T cells, with the goal of improving scalability, reducing manufacturing time, and broadening patient access. The company’s principal revenue activity has historically consisted of collaboration agreements and licensing arrangements, as it remains in the clinical development stage and has not commercialized products as of publicly available filings through 2024.

Key programs include candidates targeting CD19 and other tumor-associated antigens, supported by proprietary gene-editing and cell engineering technologies. Allogene was founded in 2017 by former Kite Pharma executives and biotechnology investors, including collaborations with academic and industry partners. The company’s strategic positioning is centered on industrial-scale manufacturing of allogeneic cell therapies and leveraging gene-editing approaches intended to reduce graft-versus-host disease and immune rejection risks.